Food & Health
Cigna (CI) will drop coverage of GLP-1 obesity drugs Wegovy and Zepbound from its own employee health plan on July 1, a move that spotlights mounting cost pressure on a drug category generating billions in annual revenue for Novo Nordisk and Eli Lilly.
For long-horizon investors, the decision by one...
Legend Biotech (LEGN) shares jumped roughly 40% on Tuesday after early Phase 1 data for its in vivo CAR-T...
McDonald’s Corporation (MCD) announced a comprehensive growth strategy focused on digital innovation...
In a China Phase 3 trial, ivonescimab—an investigational lung cancer therapy developed by Akeso and Summit...
Japan’s Shionogi & Co. has received U.S. Food and Drug Administration approval for its oral...
Revolution Medicines Inc. announced that daraxonrasib, its investigational oral treatment for pancreatic...
The European Medicines Agency has given its recommendation for approval of Novo Nordisk’s oral...
Trending
CATEGORIES
Categories
SIGNUP TO OUR NEWSLETTER
Subscribe
Get breaking market insights directly to your inbox